PD5 Professional development workshop
Establishing core facilities for measuring clinical trial outcomes
Translational
Experience from the European Cystic Fibrosis Society (ECFS) Clinical Trials Network (CTN)
Registration for this session is additional to the congress registration fee and is €40 on site, €35 standard or €25 for early bird registration.
Aims : Access educational materials here
To identify hurdles to the inclusion and acceptance of broader outcome measures in clinical trials; to describe the benefits of standardisation and the roles and requirements of a core facility giving the ECFS CTN as example; to understand potential interactions between the core facility, commercial sponsors, and the trial networks.
Target audience :
Allied health professional, Clinician, Lung function technician, Paediatrician, Pharmaceutical industry representative, Physiologist, Physiotherapist, Pulmonologist, Radiologist, Researcher, Respiratory physician, Respiratory therapist
13:00
Introduction by the chair to the concept of a clinical trials network
-
Description
1
2920
13:06
Ligthning lecture: High resolution CT as a clinical trial outcome measure: standardisation of performance and scoring
H. Tiddens(Rotterdam, Netherlands)
COI
-
Description
2
2921
13:14
Lightning lecture: Lung Clearance Index: why, how, and the lessons learned
J. Davies(London, United Kingdom)
COI
-
Description
3
2922
13:22
Lightning lecture: Nasal Potential Difference: standardisation process, issues arising and FDA approvals
I. Sermet-Gaudelus(Paris, France)
COI
-
Description
4
2923
13:30
Workshop 1: Lung Clearance Index – demonstration of devices utilised by the core facility; best practices and different approaches to communication with pharmaceutical companies
K. Bayfield(Sydney, Australia)
COI
C. Saunders(London, United Kingdom)
COI
5
2924
13:50
Workshop 2: Computed tomography – include CT scans and score sheets for delegates to view and attempt to grade themselves; address any questions regarding specific trials, other grading systems or other issues delegates have had with CT as an outcome measure
H. Tiddens(Rotterdam, Netherlands)
COI
6
2925
14:10
Workshop 3: Nasal Potential Difference (NPD) – demonstration of a video of NPD; discussion of issues delegates have had with equipment; inform about the NPD standardisation guidelines
I. Sermet-Gaudelus(Paris, France)
COI
7
2926
. . .
